Acute Lymphoblastic Leukemia
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Published in Hematology Week, June 18th, 2007
Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that treatment with epratuzumab plus standard chemotherapy is feasible and well tolerated in children with B-precursor acute lymphoblastic leukemia (ALL), producing favorable early responses in the majority of patients. Elizabeth Raetz, MD, pediatric oncologist at New York University, New York, in an oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, reported results from this multicenter feasibility/phase II study.
Fifteen patients with CD22-positive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2007-06-18)
More Articles from Hematology Week
- Burkitt Lymphoma
Malaria and Epstein-Barr virus linked to pediatric cancer in Africa - Cord Blood
Research shows cord blood comparable to matched bone marrow - Lymphoma
Adding radioimmunotherapy to chemo may help patients with lymphoma - Thrombosis
Repeated childhood stroke and venous thrombosis presents risks - Acute Promyelocytic Leukemia
Innovive Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia - Angiology
New research confirms the benefit of extended-release dipyridamole plus ASA for preventing recurrent stroke in low- and high-risk patients - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
